Belgium· BE-AMP-SAM571991-00
Jyseleca 100 mg
A filgotinib product containing filgotinib maleate, registered in Belgium by Alfasigma. The same ATC class is registered in 10 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Filgotinib is registered in 10 of 19 countries.
Countries holding a registration under ATC L04AF04 (filgotinib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Filgotinib · ATC L04AF04
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Filgotinib Maleate
- Manufacturer
- Alfasigma
- Country
- Belgium (BE)
- ATC code
- L04AF04
- ATC class
- Filgotinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 3
2 priced- be_apb4244109EUR 2502.95
- be_apb4244158EUR 841.63
- be_apb7731144
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Filgotinib in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJYSELECAAlfasigma S.p.A., Bologna
- SpainJYSELECA 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAlfasigma S.P.A.
- FinlandJyselecaALFASIGMA S.p.A.
- FranceJYSELECA 100 mg, comprimé pelliculéALFASIGMA (ITALIE)
- IrelandJyseleca 100 mg film-coated tabletsAlfasigma S.p.A
- IcelandJyselecaAlfaSigma S.p.A.
- NetherlandsJyseleca 100 mg, filmomhulde tablettenAlfasigma S.p.A.
- NorwayJyselecaAlfasigma S.p.A
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jyseleca
- Liechtenstein · Jyseleca
- Norway · Jyseleca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7ef82b8e-4ea0-427d-8d80-19f5afdeba40 GET /v1/drugs/7ef82b8e-4ea0-427d-8d80-19f5afdeba40?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Jyseleca 100 mg",
"name_fr": "Jyseleca 100 mg",
"name_nl": "Jyseleca 100 mg",
"amp_code": "SAM571991-00",
"strengths": [
"100.0000",
"100.0000",
"76.0000"
],
"pack_count": 2,
"substances": [
"Filgotinib Maleate",
"Filgotinib",
"Lactose"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Filgotinib",
"authorisation_numbers": [
"EU/1/20/1480/002",
"EU/1/20/1480/001"
]
}See everything about filgotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.